SCHEMBL574087

SCHEMBL574087

N=C(N)NC[C@H](N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFPT1 Q06210 1/20 0.46
ALOX15 P16050 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
KMT2A Q03164 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC7A11 Q9UPY5 1/20 0.41
GGT1 P19440 4/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
CASR P41180 1/20 0.38
SLC7A5 Q01650 1/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GSR P00390 1/20 0.38
CYP1A2 P05177 1/20 0.38
GRIK1 P39086 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL393844 1.00 GFPT1 (0.46) GFPT1ALOX15BLMPMP22KMT2A
SCHEMBL1527344 1.00 GFPT1 (0.46) GFPT1ALOX15BLMPMP22KMT2A
Hydrochloric Acid SCHEMBL503105 0.98 GFPT1 (0.44) GFPT1ALOX15BLMPMP22KMT2A
Hydrochloric Acid SCHEMBL17239121 0.98 GFPT1 (0.44) GFPT1ALOX15BLMPMP22KMT2A
Adipic Acid SCHEMBL8055763 0.89 BHMT (0.45) GFPT1ALOX15BLMPMP22KMT2A
SCHEMBL19371887 0.84 GFPT1 (0.32) GFPT1
SCHEMBL22122969 0.84 GFPT1 (0.32) GFPT1
SCHEMBL27644228 0.84 SLC7A5 (0.42) ALOX15BLMPMP22KMT2APTGS1
SCHEMBL27644223 0.84 SLC7A5 (0.42) ALOX15BLMPMP22KMT2APTGS1
SCHEMBL1478033 0.82 SLC7A5 (0.41) ALOX15BLMPMP22KMT2APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-26 US claimed
WO-2025094120-A1 CATIONIC PEPTIDES WITH BROAD SPECTRUM ACTIVITY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-05-08 WO claimed
EP-4493273-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES Politechnika Wroclawska (PL) 2025-01-22 EP claimed
WO-2023175356-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES POLITECHNIKA WROCLAWSKA (PL) 2023-09-21 WO claimed
US-20220372022-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2022-11-24 US claimed
CN-115246872-A Conotoxin mutant and preparation method and application thereof 中国海洋大学 2022-10-28 CN claimed
WO-2019179985-A1 INHIBITORS OF MINT AND USES THEREOF UNIVERSITY OF COPENHAGEN (DK) 2019-09-26 WO claimed
US-20260146063-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-05-28 US disclosed
US-20260115301-A1 INTRACELLULAR DELIVERY OF NUCLEIC ACIDS OHIO STATE INNOVATION FOUNDATION (US) 2026-04-30 US disclosed
EP-4717776-A2 POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS Ohio State Innovation Foundation (US) 2026-04-01 EP disclosed
US-12589088-B2 Compositions and methods for treating cancer with andrographolide and melatonin combination therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2026-03-31 US disclosed
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 US disclosed
EP-4706689-A2 COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS Entrada Therapeutics, Inc. (US) 2026-03-11 EP disclosed
US-20050136017-A1 Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin L'OREAL S.A. (FR) 2005-06-23 US disclosed
US-20050129645-A1 Hair shaping composition comprising at least one non-hydroxide imine L'OREAL 2005-06-16 US disclosed
EP-1532963-A1 Composition for straightening the hair comprising at least one imine not being an hydroxide L'OREAL (FR) 2005-05-25 EP disclosed
EP-1532960-A1 Hair styling composition containing a non-hydroxide imine L'OREAL (FR) 2005-05-25 EP disclosed
EP-1390003-A1 COMPOSITION AND METHODS FOR LANTHIONIZING KERATIN FIBERS USING AT LEAST ONE ORGANIC NUCLEOPHILE AND AT LEAST ONE HYDROXIDE ION GENERATOR L'OREAL S.A. (FR) 2004-02-25 EP disclosed
US-20020189027-A1 Composition and methods for lanthionizing keratin fibers using at least one organic nucleophile and at least one hydroxide ion generator L'OREAL S.A. (FR) 2002-12-19 US disclosed
WO-2002085317-A1 COMPOSITION AND METHODS FOR LANTHIONIZING KERATIN FIBERS USING AT LEAST ONE ORGANIC NUCLEOPHILE AND AT LEAST ONE HYDROXIDE ION GENERATOR L'OREAL S.A. (FR) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115301-A1 INTRACELLULAR DELIVERY OF NUCLEIC ACIDS SLC7A1, SRM, SLC6A19 GFPT1 653/4885ALOX15 4812/4885BLM 2170/4885
US-12589088-B2 Compositions and methods for treating cancer with andrographolide and melatonin combination therapy MTNR1A, CYP27A1, CRY2 GFPT1 1104/4885ALOX15 877/4885BLM 2981/4885
US-20260146063-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, SLC7A1, SLC6A15 GFPT1 904/4885ALOX15 4408/4885BLM 3835/4885
US-20220372022-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS DNPEP, NPEPPS, PAM GFPT1 213/4885ALOX15 3961/4885BLM 3782/4885
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES F11, F2, F12 GFPT1 3221/4885ALOX15 1843/4885BLM 3997/4885
US-20050129645-A1 Hair shaping composition comprising at least one non-hydroxide imine KRT18, INHA, H1-5 GFPT1 4730/4885ALOX15 4080/4885BLM 534/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA GFPT1 4159/4885ALOX15 4509/4885BLM 820/4885
US-20050136017-A1 Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin BHMT, KRT18, INMT GFPT1 2002/4885ALOX15 2498/4885BLM 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.